Claritev Corp: directors' dealings · United States · SEC (Form 4)

About Claritev Corp

Claritev Corp. (NYSE: CTEV) is a U.S.-listed healthcare technology, data, and analytics company in the United States, trading on the NYSE. The company was formerly known as MultiPlan and rebranded to Claritev in 2025 as part of a broader strategic reset aimed at emphasizing transparency, affordability, and data-driven decision-making across the U.S. healthcare system. Claritev traces its roots back to 1980, when it began as a New York-based hospital network, and has since evolved through organic growth and acquisitions into a national healthcare cost-management platform. Claritev’s business is organized around three core service lines. First are analytics-based services, which use algorithms and multiple data sources to detect claims overcharges, recommend fair reimbursement levels, and help clients manage medical cost inflation. Second are network-based services, where Claritev negotiates provider discounts and builds large PPO-style networks; the company describes itself as operating one of the largest independent PPO networks in the United States. Third are payment and revenue integrity services, which are designed to identify and remove improper or unnecessary charges before or after claims are paid, and to help recover underpaid premium dollars. Together, these capabilities position Claritev at the intersection of claims repricing, provider network management, and healthcare price transparency. From a competitive standpoint, Claritev markets itself as a scaled, tech-enabled intermediary serving payers, employers, patients, providers, and third parties. Its differentiation rests on a proprietary data ecosystem, decades of claims repricing experience, and increasingly on AI-enabled tools that support pricing, payment accuracy, and network optimization. The company states that it serves more than 750 healthcare payers, over 100,000 employers, 60 million consumers, and 1.4 million contracted providers, underscoring the breadth of its national footprint. Key products and solutions include its national and regional provider networks, claims intelligence offerings, price transparency tools, and network design and management services. Claritev’s core market remains the United States, although management has also highlighted selective international adjacency through strategic initiatives, including an investment in Klaim to support payment acceleration solutions across the U.S. and the MENA region. Recent highlights are constructive. In May 2026, Claritev reported first-quarter results showing revenue and Adjusted EBITDA growth, while slightly raising its full-year 2026 revenue outlook. In February 2026, the board approved a $75 million share repurchase program over five years, signaling confidence in the cash generation profile and capital allocation framework. For investors tracking U.S. healthcare services and data-enabled cost containment, Claritev remains a notable NYSE name with a large addressable market, strong operating leverage potential, and an ongoing strategic transformation.